Dendreon Corp (DNDN) 0.94 $DNDN
Will Evogene (EVGN) Report Wider-than-Expected Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:10PM CST
Evogene (EVGN) is scheduled to report third-quarter 2014 results before the opening bell on Nov 10.
MNK: 91.06 (-3.49), EVGN: 10.50 (-0.01), MON: 114.44 (-0.07), DNDN: 0.94 (+0.11)
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.70 (-0.07), MNK: 91.06 (-3.49), DNDN: 0.94 (+0.11), ICPT: 172.59 (-74.39)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 112.77 (+7.82), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), SHPG: 198.58 (-1.37), DNDN: 0.94 (+0.11), SNSS: 1.63 (-0.05), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07), XOMA: 3.81 (-0.31)
Heat Biologics Takes a New Approach to Immunotherapy
ACCESSWIRE - Mon Nov 03, 1:01PM CST
WHITEFISH, MT / ACCESSWIRE / November 3, 2014 / Immunotherapy leverages the body's own immune system to fight off diseases ranging from allergies to cancer. For example, Dendreon Corporation's (NASDAQ: DNDN) PROVENGE therapy takes the patient's own immune cells and reprograms them to attack advanced prostate cancer. These dynamics led to a 22.5% reduced risk of death with just a 1.5% discontinuance rate.
HTBX: 5.26 (-0.09), DNDN: 0.94 (+0.11), NLNK: 32.15 (-2.54), GALE: 1.95 (-0.09)
The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 11.23 (+0.16), NWBO: 5.42 (+0.33), DNDN: 0.94 (+0.11), GALE: 1.95 (-0.09)
3 Scary Stocks to Avoid
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 31, 11:55AM CDT
Source: Flickr user Mike Poresky Goblins came to Wall Street early this year when markets flirted with a crash in the beginning of October. As a result, a frightening dip in account values may have many investors tossing and turning at night...
MDVN: 112.77 (+7.82), JNJ: 108.20 (-0.81), INSY: 36.19 (-1.18), GWPH: 73.97 (-0.41), DNDN: 0.94 (+0.11), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07)
Ciclofilin Pharmaceuticals Appoints Stephen F. Keane as Senior VP of Corporate Development
GlobeNewswire - Mon Oct 27, 10:07AM CDT
Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"
, a developer of broad spectrum antiviral medications, announced today the appointment of Stephen F. Keane as Senior Vice President of Corporate Development. In this role, Mr. Keane will be responsible for structuring, negotiating and executing successful strategic alliances and co-development agreements, as well as providing general corporate development leadership to the Company.
MRK: 59.34 (+0.08), DNDN: 0.94 (+0.11), AMBI: 15.34 (-0.12)
The 1 Biotech Stock I'm Definitely Not Buying
Motley Fool Staff - Motley Fool - Tue Oct 07, 7:35AM CDT
Biotechnology stocks are notorious for roller-coaster like highs and lows, but that doesn't mean that every biotech that heads lower will climb again. Figuring out which companies are bargains and which aren't can be particularly tough in this...
DNDN: 0.94 (+0.11), AEGR: 21.58 (-0.40), ARNA: 4.26 (+0.01)
Cheap Stocks Wall Street Loves: Medivation
Sean Williams, The Motley Fool - Motley Fool - Mon Oct 06, 10:11AM CDT
To say that Wall Street and investors are in love with biopharmaceutical cancer-focused company Medivation would be a dramatic understatement. Over the trailing-three-year period shares of Medivation have galloped higher by better than 1,000%! ...
MDVN: 112.77 (+7.82), JNJ: 108.20 (-0.81), DNDN: 0.94 (+0.11)
Micro-Cap Biotechs: The Next Billion Dollar Drug Is Coming From...?
OptionVol - Thu Oct 02, 5:33PM CDT
This visualization is provided by: Capital Market Laboratories (join the queue: free trial) Micro Cap Bio-techs: Who's Investing in R&D? Note that the firms above the blue line I've drawn in are pouring in at least $0.60 into researc...
LOXO: 12.00 (+0.01), DNDN: 0.94 (+0.11), VNDA: 11.79 (-0.67), OSIR: 13.50 (-0.34), CLDN: 11.50 (-0.10), GALE: 1.95 (-0.09), CTIC: 2.13 (-0.23), OTIC: 24.09 (-0.06)
Why Northwest Biotherapeutics Inc. Stock Skyrocketed 36% in 2014
Sean Williams, The Motley Fool - Motley Fool - Fri Sep 26, 9:10AM CDT
The stock market as a whole may have swooned over the past couple of days, but that hasn't changed the fact that the broad-based S&P 500 , as well as the SPDR S&P Biotech ETF , are up notably year to date. In fact, the aforementioned...
NWBO: 5.42 (+0.33), DNDN: 0.94 (+0.11)
Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:44AM CDT
Dendreon Corp. (DNDN) was a big mover last session, as the company saw its shares rise over 9% on the day
CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), DNDN: 0.94 (+0.11), ILMN: 186.35 (-3.52)
VG, NOA, RGDX, BOFI, DSCI, DNDN Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Sep 15, 4:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Vonage Holdings Corp (NYSE:VG), North American Energy Partners Inc (NYSE:NOA), Response Genetics Inc (NASDAQ:RGDX), BofI Holding Inc (NASDAQ:BOFI), Derma Sciences Inc (NASDAQ
SCI), Dendreon Corp (NASDAQ NDN) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
DSCI: 9.06 (+0.06), BOFI: 77.99 (+0.20), NOA: 5.39 (+0.19), DNDN: 0.94 (+0.11), RGDX: 0.70 (-0.02), VG: 3.51 (+0.12)
Why Inovio Pharmaceuticals Inc. Plunged By 10% in 2014
Sean Williams, The Motley Fool - Motley Fool - Fri Sep 12, 9:10AM CDT
The biotech sector, perhaps more than any other sector, is a breeding ground for large stock moves. This is because biotech stocks are predominantly valued based on their future sales potential as well as Wall Street forecasts for how many people...
INO: 11.23 (+0.16), DNDN: 0.94 (+0.11)
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics
PR Newswire - Fri Sep 12, 7:40AM CDT
On Thursday, September 11, 2014, the NASDAQ Composite ended at 4,591.81, up 0.12%, the Dow Jones Industrial Average finished the day 0.12% lower at 17,049.00, and the S&P 500 closed at 1,997.45, up 0.09%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.83, down 0.33%, while the index has advanced 5.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Novavax Inc. (NASDAQ: NVAX), Dendreon Corporation (NASDAQ: DNDN), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
NVAX: 4.95 (-0.20), DNDN: 0.94 (+0.11), ARNA: 4.26 (+0.01), FOLD: 5.72 (-0.16), EXEL: 1.74 (+0.07)
Medivation Eyes Blockbuster As Cancer Drug Gets An OK
at Investor's Business Daily - Thu Sep 11, 4:41PM CDT
Two years ago, biotech Medivation launched its first drug -- an achievement that put it ahead of more than half the biotechs trading on the market. But as of Wednesday afternoon, as far as Wall Street was concerned, it became more than just another...
MDVN: 112.77 (+7.82), JNJ: 108.20 (-0.81), GILD: 106.45 (-0.49), DNDN: 0.94 (+0.11), AMGN: 160.25 (-0.10)
Medivation Inc's FDA Approval Could be the Deathblow for Johnson & Johnson's Blockbuster Prostate Ca
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 10, 8:42PM CDT
Johnson & Johnson 's sold over $1 billion worth of its prostate cancer drug Zytiga in the first half of the year, putting it on pace to be a blockbuster two times over . But not if Medivation and partner Astellas Pharma have anything to...
MDVN: 112.77 (+7.82), JNJ: 108.20 (-0.81), DNDN: 0.94 (+0.11)
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
NWBO: 5.42 (+0.33), MRK: 59.34 (+0.08), DNDN: 0.94 (+0.11), CLDX: 13.42 (-0.06), NLNK: 32.15 (-2.54), GALE: 1.95 (-0.09), IMUC: 0.63 (+0.01), NVS: 91.76 (-0.27)
SPDR(R) S&P Biotech ETF Receives Settlement Payment
Business Wire - Mon Aug 18, 3:00PM CDT
State Street Global Advisors announced today that the SPDR(R) S&P Biotech ETF (NYSE: XBI- News) received payment as an authorized claimant from a class action settlement related to Dendreon, Corp.
STT: 77.81 (-0.04), DNDN: 0.94 (+0.11)
Will Evogene (EVGN) Report Wider-than-Expected Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:10PM CST
Evogene (EVGN) is scheduled to report third-quarter 2014 results before the opening bell on Nov 10.
MNK: 91.06 (-3.49), EVGN: 10.50 (-0.01), MON: 114.44 (-0.07), DNDN: 0.94 (+0.11)
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.70 (-0.07), MNK: 91.06 (-3.49), DNDN: 0.94 (+0.11), ICPT: 172.59 (-74.39)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 112.77 (+7.82), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), SHPG: 198.58 (-1.37), DNDN: 0.94 (+0.11), SNSS: 1.63 (-0.05), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07), XOMA: 3.81 (-0.31)
Heat Biologics Takes a New Approach to Immunotherapy
ACCESSWIRE - Mon Nov 03, 1:01PM CST
WHITEFISH, MT / ACCESSWIRE / November 3, 2014 / Immunotherapy leverages the body's own immune system to fight off diseases ranging from allergies to cancer. For example, Dendreon Corporation's (NASDAQ: DNDN) PROVENGE therapy takes the patient's own immune cells and reprograms them to attack advanced prostate cancer. These dynamics led to a 22.5% reduced risk of death with just a 1.5% discontinuance rate.
HTBX: 5.26 (-0.09), DNDN: 0.94 (+0.11), NLNK: 32.15 (-2.54), GALE: 1.95 (-0.09)
The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 11.23 (+0.16), NWBO: 5.42 (+0.33), DNDN: 0.94 (+0.11), GALE: 1.95 (-0.09)
3 Scary Stocks to Avoid
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 31, 11:55AM CDT
Source: Flickr user Mike Poresky Goblins came to Wall Street early this year when markets flirted with a crash in the beginning of October. As a result, a frightening dip in account values may have many investors tossing and turning at night...
MDVN: 112.77 (+7.82), JNJ: 108.20 (-0.81), INSY: 36.19 (-1.18), GWPH: 73.97 (-0.41), DNDN: 0.94 (+0.11), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07)
Ciclofilin Pharmaceuticals Appoints Stephen F. Keane as Senior VP of Corporate Development
GlobeNewswire - Mon Oct 27, 10:07AM CDT
Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"
, a developer of broad spectrum antiviral medications, announced today the appointment of Stephen F. Keane as Senior Vice President of Corporate Development. In this role, Mr. Keane will be responsible for structuring, negotiating and executing successful strategic alliances and co-development agreements, as well as providing general corporate development leadership to the Company. MRK: 59.34 (+0.08), DNDN: 0.94 (+0.11), AMBI: 15.34 (-0.12)
The 1 Biotech Stock I'm Definitely Not Buying
Motley Fool Staff - Motley Fool - Tue Oct 07, 7:35AM CDT
Biotechnology stocks are notorious for roller-coaster like highs and lows, but that doesn't mean that every biotech that heads lower will climb again. Figuring out which companies are bargains and which aren't can be particularly tough in this...
DNDN: 0.94 (+0.11), AEGR: 21.58 (-0.40), ARNA: 4.26 (+0.01)
Cheap Stocks Wall Street Loves: Medivation
Sean Williams, The Motley Fool - Motley Fool - Mon Oct 06, 10:11AM CDT
To say that Wall Street and investors are in love with biopharmaceutical cancer-focused company Medivation would be a dramatic understatement. Over the trailing-three-year period shares of Medivation have galloped higher by better than 1,000%! ...
MDVN: 112.77 (+7.82), JNJ: 108.20 (-0.81), DNDN: 0.94 (+0.11)
Micro-Cap Biotechs: The Next Billion Dollar Drug Is Coming From...?
OptionVol - Thu Oct 02, 5:33PM CDT
This visualization is provided by: Capital Market Laboratories (join the queue: free trial) Micro Cap Bio-techs: Who's Investing in R&D? Note that the firms above the blue line I've drawn in are pouring in at least $0.60 into researc...
LOXO: 12.00 (+0.01), DNDN: 0.94 (+0.11), VNDA: 11.79 (-0.67), OSIR: 13.50 (-0.34), CLDN: 11.50 (-0.10), GALE: 1.95 (-0.09), CTIC: 2.13 (-0.23), OTIC: 24.09 (-0.06)
Why Northwest Biotherapeutics Inc. Stock Skyrocketed 36% in 2014
Sean Williams, The Motley Fool - Motley Fool - Fri Sep 26, 9:10AM CDT
The stock market as a whole may have swooned over the past couple of days, but that hasn't changed the fact that the broad-based S&P 500 , as well as the SPDR S&P Biotech ETF , are up notably year to date. In fact, the aforementioned...
NWBO: 5.42 (+0.33), DNDN: 0.94 (+0.11)
Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:44AM CDT
Dendreon Corp. (DNDN) was a big mover last session, as the company saw its shares rise over 9% on the day
CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), DNDN: 0.94 (+0.11), ILMN: 186.35 (-3.52)
VG, NOA, RGDX, BOFI, DSCI, DNDN Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Sep 15, 4:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Vonage Holdings Corp (NYSE:VG), North American Energy Partners Inc (NYSE:NOA), Response Genetics Inc (NASDAQ:RGDX), BofI Holding Inc (NASDAQ:BOFI), Derma Sciences Inc (NASDAQ
SCI), Dendreon Corp (NASDAQ NDN) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: DSCI: 9.06 (+0.06), BOFI: 77.99 (+0.20), NOA: 5.39 (+0.19), DNDN: 0.94 (+0.11), RGDX: 0.70 (-0.02), VG: 3.51 (+0.12)
Why Inovio Pharmaceuticals Inc. Plunged By 10% in 2014
Sean Williams, The Motley Fool - Motley Fool - Fri Sep 12, 9:10AM CDT
The biotech sector, perhaps more than any other sector, is a breeding ground for large stock moves. This is because biotech stocks are predominantly valued based on their future sales potential as well as Wall Street forecasts for how many people...
INO: 11.23 (+0.16), DNDN: 0.94 (+0.11)
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics
PR Newswire - Fri Sep 12, 7:40AM CDT
On Thursday, September 11, 2014, the NASDAQ Composite ended at 4,591.81, up 0.12%, the Dow Jones Industrial Average finished the day 0.12% lower at 17,049.00, and the S&P 500 closed at 1,997.45, up 0.09%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.83, down 0.33%, while the index has advanced 5.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Novavax Inc. (NASDAQ: NVAX), Dendreon Corporation (NASDAQ: DNDN), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
NVAX: 4.95 (-0.20), DNDN: 0.94 (+0.11), ARNA: 4.26 (+0.01), FOLD: 5.72 (-0.16), EXEL: 1.74 (+0.07)
Medivation Eyes Blockbuster As Cancer Drug Gets An OK
at Investor's Business Daily - Thu Sep 11, 4:41PM CDT
Two years ago, biotech Medivation launched its first drug -- an achievement that put it ahead of more than half the biotechs trading on the market. But as of Wednesday afternoon, as far as Wall Street was concerned, it became more than just another...
MDVN: 112.77 (+7.82), JNJ: 108.20 (-0.81), GILD: 106.45 (-0.49), DNDN: 0.94 (+0.11), AMGN: 160.25 (-0.10)
Medivation Inc's FDA Approval Could be the Deathblow for Johnson & Johnson's Blockbuster Prostate Ca
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 10, 8:42PM CDT
Johnson & Johnson 's sold over $1 billion worth of its prostate cancer drug Zytiga in the first half of the year, putting it on pace to be a blockbuster two times over . But not if Medivation and partner Astellas Pharma have anything to...
MDVN: 112.77 (+7.82), JNJ: 108.20 (-0.81), DNDN: 0.94 (+0.11)
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
NWBO: 5.42 (+0.33), MRK: 59.34 (+0.08), DNDN: 0.94 (+0.11), CLDX: 13.42 (-0.06), NLNK: 32.15 (-2.54), GALE: 1.95 (-0.09), IMUC: 0.63 (+0.01), NVS: 91.76 (-0.27)
SPDR(R) S&P Biotech ETF Receives Settlement Payment
Business Wire - Mon Aug 18, 3:00PM CDT
State Street Global Advisors announced today that the SPDR(R) S&P Biotech ETF (NYSE: XBI- News) received payment as an authorized claimant from a class action settlement related to Dendreon, Corp.
STT: 77.81 (-0.04), DNDN: 0.94 (+0.11)
